Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.45 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.45 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.65 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.53 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | GRM8 | O00222 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29399073 | 1.00 | SLC7A5 (0.65) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL1666620 | 0.98 | SLC7A5 (0.67) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL9394667 | 0.98 | SLC7A5 (0.67) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL1768639 | 0.98 | SLC7A5 (0.67) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL1666513 | 0.89 | SLC7A5 (0.56) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| Homophenylalanine SCHEMBL1318350 | 0.87 | SLC7A5 (0.73) | SLC7A5GRIK1GRIA2KIF11ANPEP | |
| SCHEMBL22851020 | 0.85 | SLC7A5 (0.51) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL25356342 | 0.83 | GRIK1 (0.54) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL3629108 | 0.83 | GRIK1 (0.54) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL6377896 | 0.83 | GRIK1 (0.54) | SLC7A5GRIK1GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-0662481-B1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5578593-A | RELEASING GROWTH HORMONES FOR ANIMALS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0662481-A1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994019367-A1 | SPIRO PIPERIDINES AND HOMOLOGS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | HTR1A 3112/4885ADRA2A 1293/4885SLC6A2 1057/4885 |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | HTR1A 3112/4885ADRA2A 1293/4885SLC6A2 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.